509 related articles for article (PubMed ID: 18473844)
1. Role of AGEs in diabetic nephropathy.
Fukami K; Yamagishi S; Ueda S; Okuda S
Curr Pharm Des; 2008; 14(10):946-52. PubMed ID: 18473844
[TBL] [Abstract][Full Text] [Related]
2. Interactions between advanced glycation end-products (AGE) and their receptors in the development and progression of diabetic nephropathy - are these receptors valid therapeutic targets.
Sourris KC; Forbes JM
Curr Drug Targets; 2009 Jan; 10(1):42-50. PubMed ID: 19149535
[TBL] [Abstract][Full Text] [Related]
3. Agents in development for the treatment of diabetic nephropathy.
Goh SY; Jasik M; Cooper ME
Expert Opin Emerg Drugs; 2008 Sep; 13(3):447-63. PubMed ID: 18764722
[TBL] [Abstract][Full Text] [Related]
4. Advanced glycation end products, oxidative stress and diabetic nephropathy.
Yamagishi S; Matsui T
Oxid Med Cell Longev; 2010; 3(2):101-8. PubMed ID: 20716934
[TBL] [Abstract][Full Text] [Related]
5. Oxidative stress in diabetic nephropathy.
Kashihara N; Haruna Y; Kondeti VK; Kanwar YS
Curr Med Chem; 2010; 17(34):4256-69. PubMed ID: 20939814
[TBL] [Abstract][Full Text] [Related]
6. Salvianolic Acid A Protects Against Diabetic Nephropathy through Ameliorating Glomerular Endothelial Dysfunction via Inhibiting AGE-RAGE Signaling.
Hou B; Qiang G; Zhao Y; Yang X; Chen X; Yan Y; Wang X; Liu C; Zhang L; Du G
Cell Physiol Biochem; 2017; 44(6):2378-2394. PubMed ID: 29262395
[TBL] [Abstract][Full Text] [Related]
7. Molecular mechanisms of diabetic nephropathy and its therapeutic intervention.
Yamagishi S; Fukami K; Ueda S; Okuda S
Curr Drug Targets; 2007 Aug; 8(8):952-9. PubMed ID: 17691932
[TBL] [Abstract][Full Text] [Related]
8. Receptor for advanced glycation end products (RAGE): a novel therapeutic target for diabetic vascular complication.
Yamagishi S; Nakamura K; Matsui T; Noda Y; Imaizumi T
Curr Pharm Des; 2008; 14(5):487-95. PubMed ID: 18289075
[TBL] [Abstract][Full Text] [Related]
9. Role of advanced glycation end products (AGEs) and oxidative stress in diabetic retinopathy.
Yamagishi S; Ueda S; Matsui T; Nakamura K; Okuda S
Curr Pharm Des; 2008; 14(10):962-8. PubMed ID: 18473846
[TBL] [Abstract][Full Text] [Related]
10. The importance of diabetic nephropathy in current nephrological practice.
Locatelli F; Canaud B; Eckardt KU; Stenvinkel P; Wanner C; Zoccali C
Nephrol Dial Transplant; 2003 Sep; 18(9):1716-25. PubMed ID: 12937216
[TBL] [Abstract][Full Text] [Related]
11. Novel approaches to the treatment of progressive renal disease.
Gilbert RE; Kelly DJ; Atkins RC
Curr Opin Pharmacol; 2001 Apr; 1(2):183-9. PubMed ID: 11714094
[TBL] [Abstract][Full Text] [Related]
12. Novel therapeutic targets for diabetic nephropathy.
Fukami K; Yamagishi S; Ueda S; Okuda S
Endocr Metab Immune Disord Drug Targets; 2007 Jun; 7(2):83-92. PubMed ID: 17584148
[TBL] [Abstract][Full Text] [Related]
13. Advanced glycation end products.
Thomas MC
Contrib Nephrol; 2011; 170():66-74. PubMed ID: 21659759
[TBL] [Abstract][Full Text] [Related]
14. Grape seed proanthocyanidins ameliorate diabetic nephropathy via modulation of levels of AGE, RAGE and CTGF.
Li X; Xiao Y; Gao H; Li B; Xu L; Cheng M; Jiang B; Ma Y
Nephron Exp Nephrol; 2009; 111(2):e31-41. PubMed ID: 19142024
[TBL] [Abstract][Full Text] [Related]
15. AGE-RAGE axis blockade in diabetic nephropathy: Current status and future directions.
Sanajou D; Ghorbani Haghjo A; Argani H; Aslani S
Eur J Pharmacol; 2018 Aug; 833():158-164. PubMed ID: 29883668
[TBL] [Abstract][Full Text] [Related]
16. AGE, RAGE, and ROS in diabetic nephropathy.
Tan AL; Forbes JM; Cooper ME
Semin Nephrol; 2007 Mar; 27(2):130-43. PubMed ID: 17418682
[TBL] [Abstract][Full Text] [Related]
17. Potential role of advanced glycosylation end products in promoting restenosis in diabetes and renal failure.
Aronson D
Med Hypotheses; 2002 Sep; 59(3):297-301. PubMed ID: 12208156
[TBL] [Abstract][Full Text] [Related]
18. MicroRNA in diabetic nephropathy: renin angiotensin, aGE/RAGE, and oxidative stress pathway.
Hagiwara S; McClelland A; Kantharidis P
J Diabetes Res; 2013; 2013():173783. PubMed ID: 24575418
[TBL] [Abstract][Full Text] [Related]
19. Advanced glycation end products and diabetic nephropathy.
Thomas MC; Forbes JM; Cooper ME
Am J Ther; 2005; 12(6):562-72. PubMed ID: 16280650
[TBL] [Abstract][Full Text] [Related]
20. Synergistic contributions of carbonyl stress and megsin in diabetic nephropathy.
Inagi R; Nangaku M; Miyata T
Ann N Y Acad Sci; 2005 Jun; 1043():605-8. PubMed ID: 16037283
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
